Clinical Trial Update: Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity [Phase 3]

View source ↗

Summary

Phase 3 neurophysiological study assessing Sativex for multiple sclerosis spasticity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Sativex (nabiximol)

Snippet

Sponsor: Almirall, S.A. | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED